Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease by Diana, A et al.
Cochrane Database of Systematic Reviews
Gamma aminobutyric acid (GABA) modulators for
amyotrophic lateral sclerosis/motor neuron disease (Review)
Diana A, Pillai R, Bongioanni P, O’Keeffe AG, Miller RG, Moore DH
Diana A, Pillai R, Bongioanni P, O’Keeffe AG, Miller RG, Moore DH.
Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease.
Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD006049.
DOI: 10.1002/14651858.CD006049.pub2.
www.cochranelibrary.com
Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
10RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
15DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
16REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Gabapentin versus placebo, Outcome 1 Adverse events. . . . . . . . . . . . . 22
24APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
29HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
29CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
29DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
29SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
30DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
30NOTES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iGamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Gamma aminobutyric acid (GABA) modulators for
amyotrophic lateral sclerosis/motor neuron disease
Andrea Diana1 , Rita Pillai1, Paolo Bongioanni2 , Aidan G O’Keeffe3, Robert G Miller4, Dan H Moore5
1Department of Biomedical Sciences, University of Cagliari, Monserrato (Cagliari), Italy. 2Neurorehabilitation Unit, Department of
Neuroscience, University of Pisa, Pisa, Italy. 3Department of Statistical Science, University College London, London, UK. 4Forbes
Norris ALS Research Center, California Pacific Medical Center, San Francisco, USA. 5Research Institute, California Pacific Medical
Center, San Francisco, CA, USA
Contact address: AndreaDiana,Department of Biomedical Sciences, University of Cagliari, CittaUniversitaria diMonserrato (Cagliari),
Monserrato (Cagliari), 09042, Italy. diana@unica.it.
Editorial group: Cochrane Neuromuscular Group.
Publication status and date: New, published in Issue 1, 2017.
Review content assessed as up-to-date: 16 August 2016.
Citation: Diana A, Pillai R, Bongioanni P, O’Keeffe AG, Miller RG, Moore DH. Gamma aminobutyric acid (GABA) modulators for
amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD006049. DOI:
10.1002/14651858.CD006049.pub2.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Imbalance of gamma aminobutyric acid (GABA) and related modulators has been implicated as an important factor in the pathogenesis
of amyotrophic lateral sclerosis (ALS), which is also known as motor neuron disease (MND). In this context, the role and mechanism
of action of gabapentin and baclofen have been extensively investigated, although with conflicting results. This is the first systematic
review to assess clinical trials of GABA modulators for the treatment of ALS.
Objectives
To examine the efficacy of gabapentin, baclofen, or other GABAmodulators in delaying the progression of ALS, and to evaluate adverse
effects of these interventions.
Search methods
On 16 August 2016, we searched the Cochrane Neuromuscular Specialised Register, Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, Embase, CINAHL Plus, AMED, and LILACS. In addition, we checked the bibliographies of the trials
found in order to identify any other trials, and contacted trial authors to identify relevant unpublished results or additional clinical
trials. On 30 August 2016, we searched two clinical trials registries.
Selection criteria
Types of studies: double-blind randomized controlled trials (RCTs) or quasi-RCTs
Types of participants: adults with a diagnosis of probable or definite ALS
Types of interventions: gabapentin, baclofen, or other GABA modulators compared with placebo, no treatment, or each other
Primary outcome: survival at one year from study enrollment
Secondary outcomes: individual rate of decline of maximum voluntary isometric contraction (MVIC), expressed as arm megascore;
rate of decline of per cent predicted forced vital capacity (FVC); rate of decline of ALS Functional Rating Scale (ALSFRS); health-
related quality of life; survival evaluated by pooling hazards; and adverse events
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Data collection and analysis
At least two review authors independently checked titles and abstracts identified by the searches. The review authors obtained and
independently analyzed original individual participant data from each included study; additional review authors and the Cochrane
Neuromuscular Managing Editor checked the outcome data. Two authors independently assessed the risk of bias in included studies.
Main results
We identified two double-blindRCTs of gabapentin treatment in ALS for inclusion in this review.We found no eligible RCTs of baclofen
or other GABAmodulators. The selected studies were phase II and phase III trials, which lasted six and nine months, respectively. They
were highly comparable because both were comparisons of oral gabapentin and placebo, performed by the same investigators. The trials
enrolled 355 participants with ALS: 80 in the gabapentin group and 72 in the placebo group in the first (phase II) trial and 101 in the
gabapentin group and 102 in the placebo group in the second (phase III) trial. Neither trial was long enough to report survival at one
year, which was our primary outcome. We found little or no difference in estimated one-year survival between the treated group and
the placebo group (78% versus 77%, P = 0.63 by log-rank test; high-quality evidence). We also found little or no difference in the rate
of decline of MVIC expressed as arm megascore, or rate of FVC decline (high-quality evidence). One trial investigated monthly decline
in the ALSFRS and quality of life measured using the 12-Item Short Form Survey (SF-12) and found little or no difference between
groups (moderate-quality evidence). The trials reported similar adverse events. Complaints that were clearly elevated in those taking
gabapentin, based on analyses of the combined data, were light-headedness, drowsiness, and limb swelling (high-quality evidence).
Fatigue and falls occurred more frequently with gabapentin than with placebo in one trial, but when we combined the data for fatigue
from both trials, there was no clear difference between the groups. We assessed the overall risk of bias in the included trials as low.
Authors’ conclusions
According to high-quality evidence, gabapentin is not effective in treating ALS. It does not extend survival, slow the rate of decline
of muscle strength, respiratory function and, based on moderate-quality evidence, probably does not improve quality of life or slow
monthly decline in the ALSFRS. Other GABA modulators have not been studied in randomized trials.
P L A I N L A N G U A G E S U M M A R Y
Gamma aminobutyric acid modulators for amyotrophic lateral sclerosis/motor neuron disease
Review question
Do medicines that promote the effects of the brain chemical gamma aminobutyric acid (GABA) delay the progression of amyotrophic
lateral sclerosis (ALS)?
Background
ALS, which is also known as motor neuron disease (MND), is a condition that affects motor neurons in the brain and spinal cord. A
person with ALS gradually loses the ability to control movement. In about two-thirds of people with ALS, the condition affects the
arms first, and difficulty walking will follow. The muscles of the throat can also become weak, which affects swallowing and speaking.
As the disease progresses, muscle wasting worsens, with stiffness, cramping and loss of the ability to move. Death generally occurs
within two to five years.
Glutamate is a chemical mediator in the brain that stimulates motor neurons. Glutamate overproduction is probably responsible for
motor neuron damage in ALS. The molecule GABA acts to lessen the effects of glutamate. Medicines that increase GABA activity
(GABAmodulators), such as gabapentin and baclofen, are possible treatments for ALS. This is the first systematic review of the evidence
from clinical trials of GABA modulators for ALS.
Study characteristics
A systematic search of the medical literature found two randomized trials of gabapentin compared with placebo (inactive treatment).
The same team of scientists performed both trials, which were sponsored by the manufacturer. The trials involved a total of 355 people
with ALS. Treatment with gabapentin lasted six and nine months. We found no trials of baclofen or other GABA modulators in ALS
that met our selection criteria. We assessed the gabapentin trials as well run and well conducted.
Key results and quality of the evidence
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Neither of the trials were long enough to for us to report survival at one year. Combined results from the two studies (based on 274
participants) provided high-quality evidence of little or no difference in estimated one-year survival, the rate of decline in respiratory
function, or rate of decline in arm strength in people treated with gabapentin compared to those treated with placebo. One trial (128
participants) measured quality of life and monthly decline in function (measured by the ALS Functional Rating Scale). There was little
or no difference in the ALS Functional Rating Scale (ALSFRS) or quality of life between the gabapentin group and the placebo group.
People who received gabapentin hadmore light-headedness, drowsiness, and limb swelling than those taking placebowhenwe combined
data from both trials (353 participants). Fatigue and falls occurred more frequently with gabapentin than with placebo in one trial, but
when we combined the data for fatigue from both trials, there was no clear difference between the groups.
In conclusion, high-quality evidence indicates that gabapentin does not extend survival or slow the rate of decline of muscle strength
or respiratory function. Moderate-quality evidence shows no effect on quality of life or decline in ALSFRS. Other GABA modulators
have not been studied in randomized trials.
The evidence is current to August 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Gabapentin compared with placebo for amyotrophic lateral sclerosis (ALS)/ motor neuron disease (M ND)
Patient or population: people with ALS/ MND
Settings: mult icenter trials performed in the USA
Intervention: gabapent in 2400 mg/ day or 3600 mg/ day
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk or value
with placebo
Corresponding risk or
value with gabapentin
Survival at 1 year
Estimated survival at 1
year based on trials of 6
and 9 months’ durat ion
77% 78% 355 (2 RCTs) ⊕⊕⊕⊕
High
No clinically or stat ist i-
cally signif icant dif f er-
ence be-
tween gabapent in and
placebo
Neither included study
was long enough to
report survival at one
year, which was the pre-
specif ied primary out-
come of the re-
view. Est imated sur-
vival (gabapent in vs
placebo) was 78% ver-
sus 77%, P = 0.63 by
log-rank test)
Rate of decline in M VIC
Expressed as arm
megascore1
Mean rate of arm
megascore decline in
control groups was - 0.
0261
The mean rate of arm
megascore decline in
gabapent in groups (see
comments) was:
• 0.005 less
decline (0.002 more to
- 345 (2 RCTs) ⊕⊕⊕⊕
High
We present the 2 tri-
als separately with an
adjustment for dif f er-
ences in slope be-
tween the two trials and
4
G
a
m
m
a
a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
m
o
d
u
la
to
rs
fo
r
a
m
y
o
tro
p
h
ic
la
te
ra
l
sc
le
ro
sis/m
o
to
r
n
e
u
ro
n
d
ise
a
se
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
0.013 less)
• 0.004 more
decline (0.010 more to
0.003 less)
f or symptom durat ion.
M iller 1996 had an un-
usually fast rate of arm
megascore decline in
the placebo group and
a shorter treatment du-
rat ion in the gabapent in
group than the placebo
group; both factors had
a signif icant ef fect on
arm megascore decline
No clinically or stat is-
t ically signif icant dif -
ference in arm megas-
core decline between
treated and placebo
groups in either trial
Rate of decline of %
predicted FVC
The rate of FCV decline
in control groups was0.
593 to 0.653
The mean rate of
FVC decline in the
gabapent in group was
0.057 more decline (0.
21 more to 0.09 less)
- 274 (2 RCTs) ⊕⊕⊕⊕
High
No clinically or stat ist i-
cally signif icant dif f er-
ence be-
tween gabapent in and
placebo
Rate of decline (per
month) of functional
rating scale (over a pe-
riod of 9 months)
Measured by ALSFRS-R
The control rate of de-
cline of ALSFRS-R was
0.0764
The rate of ALSFRS-R
decline was 0.015 less
decline (0.34 more to
0.05 less)
- 128
(1 RCT)
⊕⊕⊕©
M oderate5
No clinically or stat ist i-
cally signif icant dif f er-
ence be-
tween gabapent in and
placebo
Health- related quality
of life
Short Form 12 Health
Survey (SF-12)
Miller 2001 reported lit t le or no dif ference be-
tween treatment and placebo groups in the SF-
12 (Physical), with a mean change (± SD) of -0.03
(± 0.7) on gabapent in and -0.2 (± 0.5) on placebo
(P = 0.19)
- 128 (1 RCT) ⊕⊕⊕©
M oderate5
-
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Adverse events The trials did not report an overall adverse event
rate. Light-headedness, drowsiness, falls and
swelling were reported in both trials and were
signif icant ly more common with gabapent in than
with placebo. Adverse event report ing was in-
complete in one of the trial reports
- 353 (2 RCTs) ⊕⊕⊕⊕
High
-
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
ALS: amyotrophic lateral sclerosis; ALSFRS-R: Amyotrophic Lateral Sclerosis Funct ional Rat ing Score-Revised; CI: conf idence interval; FVC: f orced vital capacity; M ND: motor
neuron disease; M VIC: maximum voluntary isometric contract ion; RCT : randomized controlled trial; RR: risk rat io; SD: standard deviat ion; vs: versus
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1. This is the pooled mean rate of decline f rom the two studies, as reported in Miller 2001.
2. We used a linear mixed ef fect model to account for dif f erences in slopes between the two trials and for symptom durat ion.
One of the trials (the phase II, M iller 1996) had an unusually rapid placebo group decline.
3. The basis for the assumed risk is the combined f it of FVC slopes f rom the 2 included studies.
4. The basis for the assumed risk is the placebo group ALSFRS-R slope.
5. We downgraded the evidence once for imprecision (small study size), as one study with 128 part icipants provided data for
this outcome.
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B A C K G R O U N D
Description of the condition
Amyotrophic lateral sclerosis (ALS), which is also known as mo-
tor neuron disease (MND), Lou Gehrig’s or Charcot’s disease, is
a neurodegenerative disorder characterized by loss of motor neu-
rons of the cerebral cortex, brain stem, and spinal cord. The con-
dition results in progressive weakness and paralysis of voluntary
muscles, which ultimately leads to death. Median prevalence (per
100,000 population) has been estimated as 5.4 (interquartile range
(IQR) 4.06 to 7.89) in Europe and 3.4 (IQR 3.15 to 3.65) in
the USA (Chiò 2013). Although the cause of ALS remains un-
known, so-called excitotoxicity induced by an imbalance of the
excitatory neurotransmitter glutamate and inhibitory neurotrans-
mitter gamma aminobutyric acid (GABA) appears to be impor-
tant in pathogenesis, because excitotoxicity is thought to trigger
irreversible cell damage (for a review, see Rao 2004). Glutamate
has been suggested as a possible chemical insult for triggering
the slow neuronal demise and related abnormalities in glutamate
metabolism seen in ALS, which include elevated glutamate lev-
els in cerebrospinal fluid (CSF) (Plaitakis 1987; Rothstein 1991;
Shaw 1995; Spreux-Varoquaux 2002). The discovery that GABA
content is increased in the serum and CSF of people with ALS led
investigators to consider its possible contribution to ALS patho-
genesis (Niebroj-Dobosz 1999). In addition, anatomical analysis
of human postmortem brains revealed a significantly reduced ex-
pression of messenger ribonucleic acid (mRNA) for the GABA re-
ceptor subunit (alpha1-subunit) (Petri 2003). These findings cor-
respond with those of a positron emission tomography study us-
ing the ligand flumazenil that showed downregulation of GABA
receptors, which is likely to reflect a loss of interneuronal func-
tion (Lloyd 2000). However, electrophysiological measurements
revealed no correlation between the ALS hyperexcitability index
in different motor units and changes in serum and CSF levels of
GABA (Kostera 2002).
Description of the intervention
Pharmacological reversal of cortical hyperexcitability in people
with ALS has been observed after sustained treatment with GABA
modulators such as gabapentin (Caramia 2000), even though ex-
periments with rat neocortical slices found no effect of gabapentin
on GABA release because of the selective activation of presynaptic
GABA-B heteroreceptors (Parker 2004).
Baclofen is a GABA agonist with some efficacy in reducing spastic-
ity of cerebral or spinal origin in people with ALS (Norris 1979).
How the intervention might work
The above studies indicate that the mechanism of action of
gabapentin is still controversial (Taylor 1994; Taylor 1998). They
provided a rationale for undertaking clinical trials of gabapentin
in ALS, despite the fact that gabapentin is not a structural analog
of GABA (Satzinger 1994), but simply a compound with confor-
mational properties that mimic its amino acid structure (Bryans
1999). Although the evidence supporting a role forGABA is under
debate, sufficient data exist to justify trials of the GABA agonist
baclofen or the GABA modulator gabapentin in ALS.
Why it is important to do this review
While treatment for spasticity and cramps in ALS have been the
subjects of other reviews (Ashworth 2012; Baldinger 2012), no
systematic review has addressed the benefit of GABA modulators
such as gabapentin or baclofen in slowing the clinical progression
of ALS. Thus, the specific aim of this review is to assess the clinical
impact of GABA modulators as disease-modifying agents.
O B J E C T I V E S
To examine the efficacy of gabapentin, baclofen, or other GABA
modulators in delaying the progression of ALS, and to evaluate
adverse effects of these interventions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered for inclusion double-blind, randomized controlled
trials (RCTs) and quasi-RCTs of gabapentin, baclofen, or other
GABA modulators in the treatment of ALS. Quasi-RCTs use
methods of allocation that are partly systematic, such as allocation
by alternate days, date of birth, or hospital number.
Types of participants
We considered for inclusion adults with a clinical and laboratory-
supported diagnosis of probable or definite ALS that conformed to
the criteria of theWorldFederationofNeurology (WFN)Research
Group (Brooks 2000).
Types of interventions
We considered for inclusion gabapentin, baclofen, or other GABA
modulators compared with placebo, no treatment, or each other.
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Types of outcome measures
Primary outcomes
Survival at one year from study enrollment.
Secondary outcomes
1. Individual rate of decline of maximum voluntary isometric
contraction (MVIC), expressed as arm megascore.
2. Rate of decline of percent predicted forced vital capacity
(FVC).
3. Rate of decline of ALS Functional Rating Scale (ALSFRS)
(Cedarbaum 1999).
4. Health-related quality of life assessed by means of a
validated multipurpose scale, such as the 36-Item Short Form
Health Survey (Rand 2016).
5. Survival evaluated by pooling hazards using methods
described by Parmar 1998 when study data are sufficiently
detailed (i.e. when survival in each group is reported as numbers
at risk and numbers dying at follow-up intervals, e.g. quarterly or
semi-annually). If such data are not available for all studies, we
will use other approaches, such as generalized inverse variance on
reported hazard ratios and their standard errors.
6. Adverse events, namely side effects such as light-
headedness, drowsiness, weakness, daytime fatigue, nausea,
anorexia, or weight loss. We based comparisons on analyses of 2
x 2 tables summarizing numbers of events in each group,
regardless of time of occurrence.
We planned to base measurement of rates on the length of follow-
up for the trial. If the lengths of follow-up differed, we planned
to conduct a subgroup analysis to determine whether length of
follow-up influenced the rate of decline in different trials.
Search methods for identification of studies
Electronic searches
On 16 August 2016, we searched the Cochrane Neuromuscu-
lar Specialised Register, Cochrane Central Register of Controlled
Trials (CENTRAL) in the in the Cochrane Register of Studies
(CRS) online, MEDLINE (January 1966 to August 2016), Em-
base (January 1980 to August 2016), CINAHL Plus (Cumula-
tive Index to Nursing and Allied Health Literature; January 1982
to August 2016), AMED (Allied and Complementary Medicine;
January 1985 to August 2016), and LILACS (Latin American and
Caribbean Health Science Information database; January 1982 to
August 2016). On 30 August 2016, we also searched US National
Institutes ofHealthOngoingTrials Register ClinicalTrials.gov and
the World Health Organization International Clinical Trials Reg-
istry Platform (ICTRP; www.who.int/ictrp/en/).
The detailed search strategies are in the appendices: Cochrane
Neuromuscular Specialised Register (Appendix 1), MEDLINE
(Appendix 2), Embase (Appendix 3), AMED (Appendix 4),
CINAHL Plus (Appendix 5), LILACS (Appendix 6), CEN-
TRAL (Appendix 7), ClinicalTrials.gov (Appendix 8), and ICTRP
(Appendix 9).
Searching other resources
We checked the bibliographies of the trials found in order to iden-
tify references to other trials. In addition, we contacted authors of
trials to identify relevant unpublished results or clinical trials.
Data collection and analysis
Selection of studies
Two or three review authors (from among AD, DHM and RP)
independently checked all titles and abstracts identified by the
searches. The same review authors independently examined the
full-text reports of the collected papers in order to select trials that
fit the inclusion criteria for the review. There was no disagreement
on study selection.
We included a PRISMA flow chart to illustrate the study selection
process and noted the reasons for study exclusion in sufficient
detail for completion of a Characteristics of excluded studies table.
Data extraction and management
We were able to obtain the original data for each participant in
all included trials from the trial authors, two of whom are authors
of this review. For each study, we had original raw data for every
participant for all outcome endpoints. We then combined all orig-
inal data into one dataset, which facilitated statistical analyses. A
statistician independent of the trials (AO’K) and the Managing
Editor of Cochrane Neuromuscular double-checked the data in
the review to ensure accuracy.
Assessment of risk of bias in included studies
Two review authors (AD and RP) independently assessed the risk
of bias in each included study. We would have resolved disagree-
ment by consensus, but none occurred. Each review author as-
sessed the risk of bias of the studies, taking into account the fol-
lowing parameters: security of randomization, allocation conceal-
ment, blinding of participants and personnel, blinding of outcome
assessors, completeness of outcome data, selective outcome report-
ing, and other sources of bias, according to the methods set out
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We made judgements for each domain of low,
high, or unclear risk of bias. We included a ’Risk of bias’ summary
figure showing the assessments for the included studies (Figure 1).
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study. Green = low risk of bias, yellow = unclear risk of bias, red (not shown) = high risk of bias.
Data synthesis
Weobtained Individual participant data for statistical analyses.We
combined data from the two trials for meta-analysis where both
trials reported the same outcome.
Statistical methods
We obtained data from the principal investigators for each par-
ticipant in each of the clinical trials included in this review. For
survival, we combined the data from the studies into a single data
file and used the Kaplan-Meier method to estimate survival at 12
months after enrollment into the trial. We also used the log-rank
statistic to test whether participants treated with gabapentin had
longer survival than those treated with placebo.
Both studies used rate of decline in arm megascore strength
(MVIC) of eight armmuscle groups (bilateral shoulder and elbow
flexion and extension) as their primary measure of efficacy. Both
studies measured MVIC every four weeks. Raw scores for MVIC
were standardized to published norms using z-score transforma-
tions (raw score minus norm average divided by norm standard
deviation). The arm megascore was calculated as the average z-
score over all tested muscles for each participant at each visit. The
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primary outcome measure was the mean slope of the arm megas-
cores (rate of decrease over time, measured in days from initial
visit), for each participant in the intent-to-treat population, which
included all participants randomized to a study medication (active
or placebo) and having at least two visits to the center.
In the original analyses of each study a slope was estimated by
linear regression for each participant and mean slopes for treated
and placebo were compared using t-test or Mann-Whitney test.
These analyses weighted each participant equally, regardless of the
number of times each participant was evaluated.
In this meta-analysis, we pooled individual participant data from
the trials and fit a linearmixed effects (lme)model to the combined
data. This model takes into account the number of times each
participant is evaluated so that those with more evaluations receive
greater weight when estimating model parameters. The lmemodel
also estimates pooled variances rather than separate ones when
each participant is fit separately using linear regression. (The lme
model was not available for the phase II study in 1996.) We also
use the lme model to fit combined FVC data.
Our statistical model assumed that arm megascore (transformed
to average z-score) and FVC declined linearly over time. When
fitting the pooled data, the lme model included fixed-effect terms
for intercept (starting value), slope (rate of decline over time), and
change in slope for gabapentin treatment. Random effects for in-
tercept and slope allowed for person-to-person differences in slope
and intercept and an additional random effect for each partici-
pant’s deviation from the linear fit. The model is given mathemat-
ically by the formula:
Yij = (B0 + b0i) + (B1 + B2*Ii + b1i)*Tij + eij,
where i indicates participant and Tij indicates time (month of the
jth measurement in the ith participant). Capital letters indicate
fixed-effect coefficients and lower case letters are random effects.
The term Ii is an indicator equal to 1 for the ith participant on
active treatment and 0 for placebo. We also added fixed-effect
terms to test whether treatment effects differed by trial, symptom
duration, and initial arm megascore.
We used Stata version 11.0 for the above statistical analyses (Stata
2009).
Other analyses
We calculated a risk ratio (RR) with 95% CI for adverse event
outcomes using the Cochrane statistical software ReviewManager
5 (RevMan) (RevMan 2014).
We used a fixed-effect model for these analyses as the two included
trials were performed with similar methods by the same investiga-
tors, and we consider them very likely to be measuring the same
effects. We assessed heterogeneity in the meta-analyses visually
and using the Chi² test and I² statistic calculated by RevMan. We
followed guidance for rule of thumb interpretation of I² in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).
’Summary of findings’ table
We created a ’Summary of findings’ table showing the following
outcomes.
• Survival at one year from study enrollment.
• Rate of decline of MVIC.
• Rate of decline of per cent predicted FVC.
• Rate of decline (per month) of ALSFRS.
• Health-related quality of life.
• Adverse events.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness, and publication bias)
to assess the quality of a body of evidence (studies that contribute
data for the prespecified outcomes). We used methods and rec-
ommendations described in Section 8.5 and Chapter 12 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We used GRADEpro software (GRADE 2008). We used
footnotes to justify any decisions to downgrade or upgrade the
quality of studies and made comments to aid readers’ understand-
ing of the review where necessary.
Sensitivity analysis
We would have performed sensitivity analysis to investigate het-
erogeneity in the results and to assess the effect of including studies
at higher risk of bias, but this was not necessary.
R E S U L T S
Description of studies
Results of the search
Several searches were run in each database over a number of
years. The MEDLINE and Embase filters were changed to im-
prove specificity during review development. See Figure 2 for a
PRISMA flow chart illustrating the study selection process. The
combined searches found the following total number of papers in
each database.
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Figure 2. Study flow diagram.
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• MEDLINE - 40 papers
• Embase - 246 papers
• Cochrane Neuromuscular Specialised Register - 11 papers
• CENTRAL - 10 references
• CINAHL Plus - 7 references
• AMED - 0 references
• LILACS - 0 references
We considered six studies as potentially eligible after screening
titles and abstracts, but only two RCTs fulfilled selection criteria
for the review (Miller 1996; Miller 2001).
Included studies
We identified two studies that fulfilled our selection criteria (Miller
1996; Miller 2001); see Characteristics of included studies. Both
were randomized, placebo-controlled, double-blind studies based
on the enrollment of peoplewith a diagnosis of definite or probable
ALS. InMiller 1996, the intervention consisted of oral gabapentin
800 mg or placebo three times daily for six months. During Miller
2001, participants received oral gabapentin 1200 mg three times
daily or placebo for nine months.
Excluded studies
We excluded two studies that were not randomized (Caramia
2000; Kalra 2003). We excluded a nonblinded study on the
grounds that randomized participants received different doses and
schedules of gabapentin, and a nonrandomized group formed the
control group (Mazzini 1998). In Norris 1979, very few baclofen-
treated participants completed the trial and all had a fatal out-
come. The data were too meagre for analysis. See Characteristics
of excluded studies.
Risk of bias in included studies
Both studies presented a low risk of bias overall. The Miller 1996
report did not describe allocation concealment; therefore, we rated
this domain and blinding of participants as unclear. Miller 2001
was at low risk of bias for all domains other than selective outcome
reporting. which we rated as at unclear risk of bias, because the
trialists did not fully report adverse events. See the ’Risk of bias’
summary figure for an illustration of the review authors’ ’Risk of
bias’ assessments for each trial (Figure 1) and Characteristics of
included studies.
Effects of interventions
See: Summary of findings for the main comparison
Gabapentin versus placebo
Survival at one year
Not reported
Arm megascores
Overall, there was little or no difference in arm megascore decline
between the gabapentin-treated group and placebo group.
The original report of results from the phase III trial noted that
symptom duration was significantly shorter for participants as-
signed to gabapentin than for participants assigned to placebo.
This report also noted a difference in armmegascore rate of decline
in the placebo groups between the two trials. To account for these
factors, we added terms to the lme model to account for differ-
ences in slopes between the two trials and for symptom duration.
Both of these factors were significant, that is, armmegascore slopes
differed significantly in the two trials and symptom duration had
a significant effect on slopes.
Table 1 summarizes the results of fitting the combined armmegas-
core with the lme model (N = 345). Interestingly, when we fit data
from each trial separately, the effect of gabapentin was positive (i.e.
reduced slope) in the phase II trial and was negative (i.e. increased
slope) in the phase III trial. However, neither effect was statisti-
cally significant, nor was there a statistically significant difference
in effect (P = 0.19 for a differential effect; high-quality evidence).
Table 1. Results for arm megascore slopes
Mean slopes Treatment effect
Descriptor Gabapentin Placebo Mean 95% CI
Separate fits
Phase II -0.024 -0.032 0.008 (-0.001 to 0.017)
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(Continued)
Phase III -0.026 -0.022 -0.004 (-0.010 to 0.003)
Combined lme fit with
interaction terms
Phase II -0.025 -0.030 0.005 (-0.002 to 0.013)
Phase III -0.025 -0.021 -0.004 (-0.010 to 0.003)
Forced vital capacity
Gabapentin had little or no effect on FVC slope in either trial (see
Table 2). Analysis of the combined data (N = 344) also found no
little or no effect of gabapentin on slope. The lme model did not
have to be adjusted for differences in results in the two trials and
symptom duration had no effect on FVC (high-quality evidence).
Table 2. Results for FVC slopes (lme fits)
Treatment effect
Descriptor Gabapentin Placebo Mean 95% CI
Separate fits
Phase II -0.656 -0.593 -0.09 (-0.278 to 0.151)
Phase III -0.635 -0.607 -0.028 (-0.234 to 0.177)
Combined fit -0.650 -0.593 -0.057 (-0.209 to 0.094)
ALS Functional Rating Scale
Reported in Miller 2001 but not Miller 1996. The trial demon-
strated no clinically important difference in monthly rate of de-
cline in ALSFRS in the gabapentin group versus the placebo group
(moderate-quality evidence). See Table 3.
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Table 3. Monthly rates of decline for ALSFRS in phase III study
Mean slopes Treatment effect
Descriptor Gabapentin Placebo Mean 95% CI
Phase II -0.091 -0.076 0.015 -0.34 to 0.05
Health-related quality of life
Miller 2001 reported little or no difference between treatment and
placebo groups in the SF-12 (Physical), with a mean change (±
standard deviation) of -0.03 (± 0.7) in the gabapentin group and -
0.2 (± 0.5) in the placebo group (P = 0.19) (completer population,
N=128;moderate-quality evidence).Miller 1996 didnotmeasure
health-related quality of life.
Survival (pooled estimate)
There was little or no difference in estimated one-year survival be-
tween the gabapentin-treated group and the placebo group. Sur-
vival appeared to be better in the phase III study (Miller 2001)
compared to the phase II study (Miller 1996), but the log-rank
test comparing survival by trial in all participants suggested that
it could be due to chance (P = 0.11). Nevertheless, to avoid bias
due to possible improvement in ALS survival over calendar time,
we used a stratified log-rank statistic to test for a treatment effect
in the combined data. This also showed little or no difference
between the two groups (high-quality evidence). (We summarize
results in Table 4).
Table 4. Survival
Gabapentin Placebo log-rank
Trial Number of
deaths
Survival 95% CI Number of
deaths
Survival 95% CI P value*
Phase II 17/80 0.76 (0.65 to 0.85) 16/72 0.74 (0.61 to 0.84) 0.67
Phase III 6/101 0.93 (0.86 to 0.97) 7/102 0.82 (0.51 to 0.95) 0.82
Combined 23/181 0.78 (0.68 to 0.86) 23/174 0.77 (0.66 to 0.85) 0.63
*log-rank test stratified by trial in combined data
Adverse events
The two trials reported adverse events, which were similar in
kind. When we combined data from both trials (N = 353; high-
quality evidence), complaints that were elevated in those tak-
ing gabapentin were light-headedness (RR 2.80, 95% CI 1.79
to 4.40), drowsiness (RR 2.64, 95% CI 1.61 to 4.33), and limb
swelling (RR 2.70, 95% CI 1.45 to 5.02). Falls occurred more fre-
quently with gabapentin than placebo in Miller 2001, but not in
Miller 1996 (RR from the combined analysis 1.65, 95%CI 1.06 to
2.57). Miller 2001 reported only these adverse events, which were
those that occurred with a significantly greater frequency in the
gabapentin group.We have also presented the other adverse events
reported inMiller 1996 with a greater than five per cent frequency
in gabapentin or placebo groups (Analysis 1.1). Miller 1996 (N =
149) reported a greater frequency of fatigue with gabapentin than
with placebo (RR 3.84, 95% CI 1.14 to 12.92) and a lower fre-
quency of headache with gabapentin than with placebo (RR 0.51,
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95% CI 0.26 to 1.00), with little or no difference between the two
groups in other recorded events. No important heterogeneity was
apparent in the adverse event meta-analyses.
D I S C U S S I O N
Summary of main results
We identified two RCTs of gabapentin in ALS involving a total of
355 participants and performed a meta-analysis of the combined
data. The trials were to short to provide data on survival a year
after enrollment, which was the primary outcome of the review.
However, there was little or no difference in estimated survival
at one year in the gabapentin-treated group versus the placebo
group in either trial, or in the combined data. The arm megascore
was the primary outcome measure of both trials. Results from the
phase II trial showed a trend toward a slowing of the decline of
arm megascore, even though this difference did not reach a statis-
tical significance (defined as P < 0.05) (Miller 1996). Results from
the randomized phase III trial (Miller 2001), as well as analysis
of the combined arm megascore data from both trials, showed no
therapeutic benefit with gabapentin in people with ALS. FVC, the
other major outcomemeasure in these studies, is still an important
outcome measure in ALS trials because of the importance of pul-
monary function to people with ALS. Here again, there was little
or no benefit from treatment. One trial measured monthly de-
cline in the ALSFRS and quality of life using the SF-12 and found
that there was probably little or no difference between groups for
ALSFRS and quality of life. Drowsiness, light-headedness, and
limb swelling occurredmore frequently with gabapentin thanwith
placebo, based on combined analyses. Fatigue and falls occurred
more frequently with gabapentin than with placebo in one trial,
but when we combined the data for fatigue from both trials, there
was no clear difference between the groups.
Overall completeness and applicability of
evidence
In the absence of trials of baclofen and other GABA modulators,
the identified trials of gabapentin fit the overall requirements for
inclusion in the review. One of the trials did not measure quality
of life or ALSFRS (Miller 1996).
Quality of the evidence
We consider the two studies that were included to yield high-qual-
ity evidence that gabapentin is not effective in ALS. We did not
consider these studies to be completely free of any risk of bias, but
both had adequate blinding, sequence generation and outcome re-
porting. We therefore assessed the risk of bias in these trials as low.
We identified no reasons for downgrading the quality of the evi-
dence based on the GRADE criteria of indirectness, inconsistency,
publication bias, or study limitations. We downgraded quality of
life and decline in ALSFRS outcomes for imprecision due to the
small sample size (128 participants) of the one trial that provided
data.
Potential biases in the review process
Review authors who were not investigators in the trials assessed
risk of bias in the selected studies. DM was the statistician in both
included studies and performed data extraction and entry for this
review. He provided outcome data for checking by other review
authors and the Cochrane Neuromuscular Managing Editor.
Agreements and disagreements with other
studies or reviews
ACochrane review reported that gabapentin had no benefit in trial
participants with type II and III spinal muscular atrophy (SMA),
which is another, more slowly progressive, motor neuron disease
(Wadman 2012).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
According to high-quality evidence, gabapentin is not effective
in treating amyotrophic lateral sclerosis (ALS), because it neither
halts nor slows progression of ALS. Gabapentin does not improve
estimated survival at one year nor slow the rate of decline of muscle
strength or respiratory function. Gabapentin probably has little or
no effect on quality of life or monthly decline in ALS functional
rating scale. No evidence from randomized trials was available for
other gamma aminobutyric acid (GABA)-modulating treatments.
Implications for research
Further studies of gabapentin to slow progression of ALS are un-
likely to be fruitful. The literature provides no indication of alter-
native promising GABA modulators.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Miller 1996
Methods Randomized, placebo-controlled, double-blind study
Participants Country: USA
Multicenter: 8 sites
Diagnosis: definite or probable ALS
Number of participants: 152 (3 not included in the ITT analysis), 79 treated (52 male,
27 female), 70 placebo (50 male, 20 female)
Age: mean 60.3 years (treated), 56.4 years (placebo)
Inclusion criteria: people between21 and85 years of agewho had a clinical and laboratory
supported diagnosis of ALS with symptoms for no more than 3 years prior to the study
Exclusion criteria: a FVC of less than 60% of the predicted value or exclusively bulbar
symptoms. For safety, the trialists also excluded people with severe bulbar involvement
Interventions Oral gabapentin 800 mg or placebo 3 times daily for 6 months
Outcomes Primary: MVIC strength of 8 arm muscle groups (bilateral shoulder and elbow flexion
and extension). Both MVIC and FVC were measured every 4 weeks
Secondary: rates of decline of FVC (per cent predicted) and arm megascore slope for the
completer population (those who had completed all 6 monthly visits)
Funding “Supported by Parke-Davis. The investigators received no financial incentives such as
equity interest, patent rights, or corporate affiliation. Compensation was provided only
for some of the costs of the study and not for reimbursement of investigator time in
carrying out the trial.”
Conflicts of interest Not stated. Report lists 4 authors inWestern Amyotrophic Lateral Sclerosis Study Group
under the affiliation “Parke-Davis”
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients randomly assigned”
Allocation concealment (selection bias) Unclear risk Comment: not addressed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Light-headedness affecting more partici-
pants in the gabapentin groupmay have re-
sulted in some unblinding
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Miller 1996 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Clinical evaluators who measured the
MVC [MVIC] were blinded and did not
discuss adverse events with patients”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 35 dropouts (17 placebo, 18 gabapentin).
Reasons were: adverse events (12), includ-
ing 4 deaths (2 placebo, 2 drug), noncom-
pliance (6), advancingweakness and inabil-
ity to attend study center (3), left to par-
ticipate in another trial (9), eliminated be-
cause of inappropriate enrollment (2), lost
to follow-up (3). 5 participants took 2000
mg gabapentin/day, but could not tolerate
2400 mg/day
152 participants were recruited; ITT analy-
sis for the primary outcome was performed
on 149 participants (excluding 3 people
who only had one study visit)
A high risk of bias for secondary outcomes
measured in the “completer population”,
which was those completing all 6 monthly
visits)
Selective reporting (reporting bias) Low risk Outcomes reported as specified inmethods
Adverse event reporting comprehensive
Other bias Low risk Adequate
Miller 2001
Methods Randomized, placebo-controlled, double-blind study
Participants Country: USA
Multicenter: 8 sites
Diagnosis: definite or probable ALS
Number of participants: 204 (8 not included in the intent-to-treat analysis), 102 treated,
102 placebo
Age: 21 to 85 years
Inclusion criteria: people who had a clinical and laboratory supported diagnosis of ALS
with symptoms for no more than 3 years prior to the study
Exclusion criteria: FVC of less than 60% of predicted, exclusively bulbar symptoms and
concomitant use of riluzole
Interventions Oral gabapentin 1200 mg or placebo 3 times daily for 9 months
Outcomes Primary: rate of decline in MVIC strength of 8 arm muscle groups (bilateral shoulder
and elbow flexion and extension)
Secondary: median rate of rate of decline of per cent predictedMVIC, FVC, armmegas-
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Miller 2001 (Continued)
core slope for completers of study and participants above 50th percentile of strength
at baseline, and rate of decline of per cent predicted FVC. Investigators also recorded
change during 9 months in ALSFRS, timed walking (15 feet), rapid foot taps, mortality,
SF-12, and a symptom survey
Funding “Supported by MDA, Warner Lambert Parke Davis, and the US FDA Office of Orphan
Products Development (grant # FD-R-001656-01)”
Conflicts of interest Not stated
Notes 9-month randomized phase followed by a 6-month open follow-up (not reported in the
review)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients randomly assigned”
“The randomization was accomplished by
the research pharmacist at the coordinat-
ing site and the allocation of patients was
known only to her”
Allocation concealment (selection bias) Low risk “The randomization was accomplished by
the research pharmacist at the coordinat-
ing site and the allocation of patients was
known only to her”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded, placebo-controlled. “All
capsules were identical in appearance”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded, placebo-controlled
Incomplete outcome data (attrition bias)
All outcomes
Low risk Negative correlations between the dropout
rate and initial FVC per cent (P = 0.03) and
initial arm strengthmegascore,measured as
a percentage of normal (P = 0.003); those
with lower initial values were more likely
to drop out
204 randomized, 102 to each group. Pre-
mature withdrawals: 27 in gabapentin
group, 30 in placebo group. At the 9-
month termination visit, 65 participants
remained in the gabapentin group and 63
participants in the placebo group. Primary
outcome measure was based on ITT pop-
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ulation of 196/204 participants (4% loss)
Selective reporting (reporting bias) Unclear risk Low risk for efficacy outcomes, which were
reported as specified in methods
High risk of bias for adverse events. The re-
port presented data only for adverse events
occurring with a greater frequency in the
gabapentin group
Other bias Low risk Adequate
ALS: amyotrophic lateral sclerosis
FVC: forced vital capacity
ITT: intention-to-treat
MVIC: maximum voluntary isometric contraction
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Caramia 2000 Non-randomized and uncontrolled
Kalra 2003 Non-randomized
Mazzini 1998 Not blinded. Trialists considered a (nonrandomized) group of participants treated with symptomatic treatments as
a control group. Randomized participants received different doses and schedules of gabapentin
Norris 1979 Only 20 participants were enrolled in this baclofen trial (9 receiving baclofen and 11 receiving placebo). The 5
participants possibly experiencing beneficial effects had a fatal outcome. The data were too meagre for analysis
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D A T A A N D A N A L Y S E S
Comparison 1. Gabapentin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse events 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Light-headedness 2 353 Risk Ratio (M-H, Fixed, 95% CI) 2.80 [1.79, 4.40]
1.2 Drowsiness 2 353 Risk Ratio (M-H, Fixed, 95% CI) 2.64 [1.61, 4.33]
1.3 Falls 2 353 Risk Ratio (M-H, Fixed, 95% CI) 1.65 [1.06, 2.57]
1.4 Limb swelling 2 353 Risk Ratio (M-H, Fixed, 95% CI) 2.70 [1.45, 5.02]
1.5 Headache 1 149 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.26, 1.00]
1.6 Weakness 1 149 Risk Ratio (M-H, Fixed, 95% CI) 2.07 [0.84, 5.09]
1.7 Fatigue 1 149 Risk Ratio (M-H, Fixed, 95% CI) 3.84 [1.14, 12.92]
1.8 Diarrhea 1 149 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [0.49, 4.13]
1.9 Cramps 1 149 Risk Ratio (M-H, Fixed, 95% CI) 3.54 [0.78, 16.14]
1.10 Shortness of breath 1 149 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.24, 2.31]
1.11 Depression 1 149 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.31, 3.96]
1.12 Nausea 1 149 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.09, 1.20]
Analysis 1.1. Comparison 1 Gabapentin versus placebo, Outcome 1 Adverse events.
Review: Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease
Comparison: 1 Gabapentin versus placebo
Outcome: 1 Adverse events
Study or subgroup Gabapentin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Light-headedness
Miller 1996 29/79 8/70 39.5 % 3.21 [ 1.57, 6.56 ]
Miller 2001 33/102 13/102 60.5 % 2.54 [ 1.42, 4.53 ]
Subtotal (95% CI) 181 172 100.0 % 2.80 [ 1.79, 4.40 ]
Total events: 62 (Gabapentin), 21 (Placebo)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 4.49 (P < 0.00001)
2 Drowsiness
Miller 1996 20/79 8/70 45.9 % 2.22 [ 1.04, 4.71 ]
Miller 2001 30/102 10/102 54.1 % 3.00 [ 1.55, 5.81 ]
0.2 0.5 1 2 5
Favours gabapentin Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Gabapentin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 181 172 100.0 % 2.64 [ 1.61, 4.33 ]
Total events: 50 (Gabapentin), 18 (Placebo)
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 3.84 (P = 0.00012)
3 Falls
Miller 1996 13/79 10/70 41.4 % 1.15 [ 0.54, 2.46 ]
Miller 2001 30/102 15/102 58.6 % 2.00 [ 1.15, 3.49 ]
Subtotal (95% CI) 181 172 100.0 % 1.65 [ 1.06, 2.57 ]
Total events: 43 (Gabapentin), 25 (Placebo)
Heterogeneity: Chi2 = 1.32, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 2.20 (P = 0.027)
4 Limb swelling
Miller 1996 7/79 1/70 8.8 % 6.20 [ 0.78, 49.18 ]
Miller 2001 26/102 11/102 91.2 % 2.36 [ 1.23, 4.52 ]
Subtotal (95% CI) 181 172 100.0 % 2.70 [ 1.45, 5.02 ]
Total events: 33 (Gabapentin), 12 (Placebo)
Heterogeneity: Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 3.15 (P = 0.0017)
5 Headache
Miller 1996 11/79 19/70 100.0 % 0.51 [ 0.26, 1.00 ]
Subtotal (95% CI) 79 70 100.0 % 0.51 [ 0.26, 1.00 ]
Total events: 11 (Gabapentin), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
6 Weakness
Miller 1996 14/79 6/70 100.0 % 2.07 [ 0.84, 5.09 ]
Subtotal (95% CI) 79 70 100.0 % 2.07 [ 0.84, 5.09 ]
Total events: 14 (Gabapentin), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
7 Fatigue
Miller 1996 13/79 3/70 100.0 % 3.84 [ 1.14, 12.92 ]
Subtotal (95% CI) 79 70 100.0 % 3.84 [ 1.14, 12.92 ]
Total events: 13 (Gabapentin), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
8 Diarrhea
Miller 1996 8/79 5/70 100.0 % 1.42 [ 0.49, 4.13 ]
Subtotal (95% CI) 79 70 100.0 % 1.42 [ 0.49, 4.13 ]
Total events: 8 (Gabapentin), 5 (Placebo)
Heterogeneity: not applicable
0.2 0.5 1 2 5
Favours gabapentin Favours placebo
(Continued . . . )
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Study or subgroup Gabapentin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.64 (P = 0.52)
9 Cramps
Miller 1996 8/79 2/70 100.0 % 3.54 [ 0.78, 16.14 ]
Subtotal (95% CI) 79 70 100.0 % 3.54 [ 0.78, 16.14 ]
Total events: 8 (Gabapentin), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
10 Shortness of breath
Miller 1996 5/79 6/70 100.0 % 0.74 [ 0.24, 2.31 ]
Subtotal (95% CI) 79 70 100.0 % 0.74 [ 0.24, 2.31 ]
Total events: 5 (Gabapentin), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
11 Depression
Miller 1996 5/79 4/70 100.0 % 1.11 [ 0.31, 3.96 ]
Subtotal (95% CI) 79 70 100.0 % 1.11 [ 0.31, 3.96 ]
Total events: 5 (Gabapentin), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
12 Nausea
Miller 1996 3/79 8/70 100.0 % 0.33 [ 0.09, 1.20 ]
Subtotal (95% CI) 79 70 100.0 % 0.33 [ 0.09, 1.20 ]
Total events: 3 (Gabapentin), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.093)
Test for subgroup differences: Chi2 = 33.38, df = 11 (P = 0.00), I2 =67%
0.2 0.5 1 2 5
Favours gabapentin Favours placebo
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A P P E N D I C E S
Appendix 1. Cochrane Neuromuscular Specialised Register (CRS) search strategy
#1 MeSH DESCRIPTOR Motor Neuron Disease Explode All [REFERENCE] [STANDARD]
#2 “moto? neuron? disease?” or “moto?neuron? disease?” [REFERENCE] [STANDARD]
#3 “charcot disease” [REFERENCE] [STANDARD]
#4 “amyotrophic lateral sclerosis” [REFERENCE] [STANDARD]
#5 als:ti or als:ab or nmd:ti or mnd:ab [REFERENCE] [STANDARD]
#6 #1 or #2 or #3 or #4 or #5 [REFERENCE] [STANDARD]
#7 MeSH DESCRIPTOR GABA Agonists Explode All [REFERENCE] [STANDARD]
#8 gabapentin or baclofen or gaba [REFERENCE] [STANDARD]
#9 MeSH DESCRIPTOR gamma-Aminobutyric Acid Explode All [REFERENCE] [STANDARD]
#10 MeSH DESCRIPTOR GABA Agonists Explode All [REFERENCE] [STANDARD]
#11 MeSH DESCRIPTOR GABA Antagonists Explode All [REFERENCE] [STANDARD]
#12 #7 or #8 or #9 or #10 or #11 [REFERENCE] [STANDARD]
#13 #6 and #12 [REFERENCE] [STANDARD]
#14 (#6 and #12) AND (INREGISTER) [REFERENCE] [STANDARD]
Appendix 2. MEDLINE (OvidSP) search strategy
Ovid MEDLINE(R) 1946 to August Week 1 2016
Database: Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
<1946 to Present>
Search Strategy:
--------------------------------------------------------------------------------
1 randomized controlled trial.pt. (428443)
2 controlled clinical trial.pt. (91561)
3 randomized.ab. (367149)
4 placebo.ab. (177912)
5 clinical trials as topic.sh. (178961)
6 randomly.ab. (261690)
7 trial.ti. (160523)
8 or/1-7 (1060915)
9 exp animals/ not humans.sh. (4299403)
10 8 not 9 (978261)
11 exp Motor Neuron Disease/ (22613)
12 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease).mp. (7547)
13 ((Lou Gehrig$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 disease)).mp. (154)
14 charcot disease.tw. (20)
15 Amyotrophic Lateral Sclerosis.mp. (21046)
16 or/11-15 (29721)
17 gabapentin.mp. (5430)
18 Baclofen/ (5141)
19 baclofen.mp. (7211)
20 exp gamma-Aminobutyric Acid/ (40627)
21 GABA.mp. (62569)
22 exp GABA Agonists/ (11455)
23 GABA Agonists.mp. (4391)
24 exp GABA Antagonists/ (26110)
25 GABA antagonists.mp. (6538)
26 or/17-25 (94735)
25Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
27 10 and 16 and 26 (19)
28 remove duplicates from 27 (17)
Appendix 3. Embase (OvidSP) search strategy
Database: Embase <1980 to 2016 Week 33>
Search Strategy:
--------------------------------------------------------------------------------
1 crossover-procedure.sh. (48263)
2 double-blind procedure.sh. (130713)
3 single-blind procedure.sh. (22711)
4 randomized controlled trial.sh. (413467)
5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1286143)
6 trial.ti. (205330)
7 or/1-6 (1437908)
8 (animal/ or nonhuman/ or animal experiment/) and human/ (1511233)
9 animal/ or nonanimal/ or animal experiment/ (3615050)
10 9 not 8 (2986322)
11 7 not 10 (1324199)
12 limit 11 to embase (1091515)
13 motor neuron disease/ or amyotrophic lateral sclerosis/ (33372)
14 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease$1).mp. (11166)
15 ((Lou Gehrig$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 disease)).mp. (178)
16 charcot disease.tw. (24)
17 amyotrophic lateral sclerosis.tw. (21818)
18 or/13-17 (36952)
19 Gabapentin.mp. (24567)
20 Gabapentin/ (23903)
21 gabapentin.mp. (24567)
22 Baclofen/ (15122)
23 baclofen.mp. (15808)
24 4 Aminobutyric Acid/ (44622)
25 gamma-aminobutyric acid.mp. (22536)
26 gamma amino butyric acid.mp. (1741)
27 GABA.mp. (56113)
28 exp 4 Aminobutyric Acid Receptor Stimulating Agent/ (66028)
29 GABA agonists.mp. (727)
30 exp 4 Aminobutyric Acid Receptor Blocking Agent/ (18889)
31 GABA antagonists.mp. (480)
32 or/19-31 (118086)
33 12 and 18 and 32 (52)
34 remove duplicates from 33 (52)
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Appendix 4. AMED (OvidSP) search strategy
Database: AMED (Allied and Complementary Medicine) <1985 to August 2016>
Search Strategy:
--------------------------------------------------------------------------------
1 Randomized controlled trials/ (1794)
2 Random allocation/ (313)
3 Double blind method/ (595)
4 Single-Blind Method/ (77)
5 exp Clinical Trials/ (3561)
6 (clin$ adj25 trial$).tw. (6444)
7 ((singl$ or doubl$ or treb$ or trip$) adj25 (blind$ or mask$ or dummy)).tw. (2686)
8 placebos/ (571)
9 placebo$.tw. (2906)
10 random$.tw. (16032)
11 research design/ (1859)
12 Prospective Studies/ (920)
13 meta analysis/ (187)
14 (meta?analys$ or systematic review$).tw. (2916)
15 control$.tw. (32885)
16 (multicenter or multicentre).tw. (925)
17 ((study or studies or design$) adj25 (factorial or prospective or intervention or crossover or cross-over or quasi-experiment$)).tw.
(11834)
18 or/1-16 (45582)
19 exp Motor Neuron Disease/ (109)
20 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease).mp. (182)
21 ((Lou Gehrig$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 disease)).mp. (2)
22 charcot disease.tw. (1)
23 Amyotrophic Lateral Sclerosis/ (205)
24 amyotrophic lateral sclerosis.tw. (285)
25 or/19-24 (441)
26 gabapentin.mp. (66)
27 Baclofen/ (68)
28 baclofen.mp. (142)
29 GABA.mp. (136)
30 gamma aminobutyric acid.mp. (43)
31 or/26-29 (328)
32 18 and 25 and 30 (0)
Appendix 5. CINAHL (EBSCOhost) search strategy
Tuesday, August 16, 2016 11:04:07 AM
S29 S18 and S23 and S28 7
S28 S24 or S25 or S26 or S27 4,785
S27 gabapentin or baclofen or gaba 4,785
S26 (MH “GABA”) or (MH “GABA Agonists”) or (MH “GABA Antagonists”) 1,976
S25 (MH “Baclofen”) 817
S24 (MH “Gabapentin”) 731
S23 S19 or S20 or S21 or S22 6,855
S22 (Lou Gehrig* W5 syndrome*) or (Lou Gehrig* w5 disease*) 36
S21 amyotrophic lateral sclerosis 3,029
S20 motor neuron disease or motor neurone disease or motoneuron* disease or motorneuron* disease 1,269
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S19 (MH “Motor Neuron Diseases+”) 6,261
S18 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 849,892
S17 ABAB design* 92
S16 TI random* or AB random* 177,482
S15 ( TI (cross?over or placebo* or control* or factorial or sham? or dummy) ) or ( AB (cross?over or placebo* or control* or factorial
or sham? or dummy) ) 352,654
S14 ( TI (clin* or intervention* or compar* or experiment* or preventive or therapeutic) or AB (clin* or intervention* or compar* or
experiment* or preventive or therapeutic) ) and ( TI (trial*) or AB (trial*) ) 128,261
S13 ( TI (meta?analys* or systematic review*) ) or ( AB (meta?analys* or systematic review*) ) 47,819
S12 ( TI (single* or doubl* or tripl* or trebl*) or AB (single* or doubl* or tripl* or trebl*) ) and ( TI (blind* or mask*) or AB (blind*
or mask*) ) 27,392
S11 PT (“clinical trial” or “systematic review”) 131,810
S10 (MH “Factorial Design”) 975
S9 (MH “Concurrent Prospective Studies”) or (MH “Prospective Studies”) 286,742
S8 (MH “Meta Analysis”) 24,984
S7 (MH “Solomon Four-Group Design”) or (MH “Static Group Comparison”) 49
S6 (MH “Quasi-Experimental Studies”) 7,952
S5 (MH “Placebos”) 9,774
S4 (MH “Double-Blind Studies”) or (MH “Triple-Blind Studies”) 33,819
S3 (MH “Clinical Trials+”) 201,391
S2 (MH “Crossover Design”) 13,883
S1 (MH“RandomAssignment”) or (MH“RandomSample”) or (MH“Simple RandomSample”) or (MH“StratifiedRandom Sample”)
or (MH “Systematic Random Sample”) 73,290
Appendix 6. LILACS (IAHx) search strategy
(MH:C10.574.562$ or “motoneuron disease” or “motor neurone disease” or “motor neuron disease” or “enfermedad de la neurona
motor” or “doenca dos neuroniosmotores” or “amyotrophic lateral sclerosis” or “Esclerosis AmiotróficaLateral” or “EscleroseAmiotrófica
Lateral” or “LouGehrigDisease”) and (MH:D02.241.081.160.050.350$ or gabapentin or baclofen) and ((PT:“RandomizedControlled
Trial” or “Randomized Controlled trial” or “Ensayo Clínico Controlado Aleatorio” or “Ensaio Clínico Controlado Aleatório” or PT:
“Controlled Clinical Trial” or “Ensayo Clínico Controlado” or “Ensaio Clínico Controlado” or “Random allocation” or “Distribución
Aleatoria” or “Distribuição Aleatória” or randon$ or Randomized or randomly or “double blind” or “duplo-cego” or “duplo-cego” or
“single blind” or “simples-cego” or “simples cego” or placebo$ or trial or groups) AND NOT (B01.050$ AND NOT (humans or
humanos or humanos)))
Appendix 7. CENTRAL (CRSO) search strategy
Search run on Tue Aug 16 2016
#1 MESH DESCRIPTOR Motor Neuron Disease EXPLODE ALL TREES 346
#2 (“motor neuron disease” OR “motor neurone disease” OR “motoneuron disease” OR “motoneurone disease” OR “amyotrophic
lateral sclerosis”):TI,AB,KY 567
#3 #1 or #2 599
#4 MESH DESCRIPTOR gamma-Aminobutyric Acid EXPLODE ALL TREES 1124
#5 MESH DESCRIPTOR GABA Agonists EXPLODE ALL TREES 288
#6 MESH DESCRIPTOR GABA Antagonists EXPLODE ALL TREES 413
#7 gabapentin or baclofen or GABA 2452
#8 #4 OR #5 OR #6 OR #73 201
#9 #3 AND #8 10
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Appendix 8. ClinicalTrials.gov search strategy
(motor neuron disease OR amyotrophic lateral sclerosis) AND (GABA OR baclofen OR gabapentin)
Appendix 9. WHO international Clinical Trials Registry Platform search strategy
motor neuron disease AND gaba
motor neuron disease AND gabapentin
motor neuron disease AND baclofen
amyotrophic lateral sclerosis AND gaba
amyotrophic lateral sclerosis AND gabapentin
amyotrophic lateral sclerosis AND baclofen
H I S T O R Y
Protocol first published: Issue 2, 2006
Review first published: Issue 1, 2017
Date Event Description
24 August 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
AD drafted the protocol and carried out the literature searches and the review with PB and RM. RP replaced Valeria Sogos at the review
stage. DM and RM provided the data from the two trials and DM carried out the statistical analyses. As DM was an author of the
included studies, AO’K carried out an independent data extraction and checked statistical analysis using available data.
D E C L A R A T I O N S O F I N T E R E S T
Andrea Diana: none known.
Rita Pillai: none known.
Paolo Bongioanni: none known.
Aidan G O’Keeffe: none known.
Robert G Miller: conducted two of the clinical trials of gabapentin (Miller 1996; Miller 2001). He also served on the advisory board
of the ALS CARE program, which was the recipient of an unrestricted grant from the manufacturer of the drug riluzole.
Dan H Moore: conducted two of the clinical trials of gabapentin (Miller 1996; Miller 2001). He also served on the advisory board of
the ALS CARE program, which was the recipient of an unrestricted grant from the manufacturer of the drug riluzole.
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S O U R C E S O F S U P P O R T
Internal sources
• Department of Neuroscience, University of Pisa, Italy.
• Department of Neurosciences, California Pacific Medical Center, San Francisco, USA.
• Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
• Department of Biomedical Sciences, University of Cagliari, Italy.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
RP replaced Valeria Sogos, who was an author of the Cochrane protocol (Diana 2006). AO’K joined the authors at the review stage.
The current Cochrane ’Risk of bias’ methodology (Higgins 2011) replaced the assessment of methodological quality described in the
protocol. We included a ’Summary of findings’ table and PRISMA flow chart, according to Cochrane requirements developed since
publication of the protocol.
This review has also reported adverse effects of included interventions; we analysed adverse events using risk ratios and 95% confidence
intervals. We did not plan these analyses in the original protocol.
As a change from protocol, at least two and sometimes three authors independently checked titles and abstracts retrieved by the searches.
N O T E S
Further research in this area is unlikely and no update is currently planned for this review.
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